Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.
Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.
Don’t give me that ‘hindsight is 20/20’, it was the first thought I had when I heard about this.
‘How are they going to monetize this?’
Either they sell your data, or they go under and… sell your data.
There was no other option from the inception.
None of this is new, and private companies gobbling up any data they can hasn’t been new since at least 2005.